PINACIDIL - Generic Drug Details

What are the generic drug sources for pinacidil and what is the scope of patent protection?

Pinacidil is the generic ingredient in one branded drug marketed by Leo Pharm and is included in one NDA. Additional information is available in the individual branded drug profile pages.

Summary for PINACIDIL

US Patents:	0
Tradenames:	1
Applicants:	1
NDAs:	1
Raw Ingredient (Bulk) Api Vendors:	69
DailyMed Link:	PINACIDIL at DailyMed

Medical Subject Heading (MeSH) Categories for PINACIDIL

Antihypertensive Agents

Membrane Transport Modulators

Vasodilator Agents

Anatomical Therapeutic Chemical (ATC) Classes for PINACIDIL

C02DG	Guanidine derivatives
C02D	ARTERIOLAR SMOOTH MUSCLE, AGENTS ACTING ON
C02	ANTIHYPERTENSIVES
C	Cardiovascular system

US Patents and Regulatory Information for PINACIDIL

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Leo Pharm	PINDAC	pinacidil	CAPSULE, EXTENDED RELEASE;ORAL	019456-002	Dec 28, 1989		DISCN	No	No
Leo Pharm	PINDAC	pinacidil	CAPSULE, EXTENDED RELEASE;ORAL	019456-001	Dec 28, 1989		DISCN	No	No

Pinacidil Market Dynamics and Financial Trajectory: Regulatory Status, Commercial Outlook, and Patent Risk

Last updated: September 4, 2026

Pinacidil has no established U.S. pharmaceutical market, no FDA-approved product, no current Orange Book listing, and no publicly reported branded revenue stream. The compound was developed as an ATP-sensitive potassium-channel opener for hypertension but did not achieve durable commercial adoption. Its present economic value is concentrated in research use, ion-channel pharmacology, and possible future drug-discovery applications rather than prescription sales.

What is pinacidil and how does it work?

Pinacidil is a potassium-channel opener that activates ATP-sensitive potassium channels, producing vascular smooth-muscle relaxation and reduced blood pressure. Its chemical name is N-cyano-N'-4-pyridyl-N''-1,2,2-trimethylpropylguanidine. The compound is commonly identified by the research code P1075 and has been studied in cardiovascular, smooth-muscle, dermatologic, and electrophysiologic applications.[1]

Pinacidil acts primarily through potassium-channel activation rather than through the calcium-channel blockade, renin-angiotensin inhibition, or sympathetic modulation used by most modern antihypertensive drugs. Its pharmacologic activity made it useful as an experimental tool for studying:

• ATP-sensitive potassium channels
• Vascular tone and vasodilation
• Cardiac electrophysiology
• Hair-follicle growth mechanisms
• Smooth-muscle contractility

Clinical development was limited by safety and tolerability concerns, including reflex tachycardia, fluid retention, headache, flushing, and hypertrichosis. These liabilities reduced its competitiveness against better-established antihypertensive classes.

What is the FDA regulatory status of pinacidil?

Pinacidil is not an FDA-approved human prescription drug. It does not have an FDA-approved New Drug Application, an FDA-approved label in Drugs@FDA, or a listed U.S. reference product.[2]

Regulatory category	Pinacidil status
FDA-approved human drug	No
U.S. reference listed drug	No
Orange Book listing	No identified listing
U.S. pediatric exclusivity	None identified
U.S. orphan-drug exclusivity	None identified
U.S. new chemical entity exclusivity	None currently available
U.S. Paragraph IV litigation	No commercial pathway identified
U.S. biosimilar pathway	Not applicable
Current FDA-approved indication	None

Pinacidil’s absence from the FDA approval system prevents a conventional generic-launch analysis. A company cannot file an Abbreviated New Drug Application against an active U.S. reference product that does not exist. A new sponsor would generally need to pursue an investigational and full NDA pathway, unless developing a different legally supportable route based on a previously approved product in another jurisdiction.

Has pinacidil been approved outside the United States?

Pinacidil was developed and marketed historically as an antihypertensive in certain non-U.S. markets, including under the Pindac name. Its commercial use did not develop into a durable global franchise. Product availability has declined or ended, and the compound is now primarily encountered in research literature and laboratory catalogs rather than active national formularies.[1,3]

Publicly available sources do not establish a current global commercial footprint comparable to marketed antihypertensive drugs such as amlodipine, losartan, lisinopril, or minoxidil.

When did pinacidil lose exclusivity?

Pinacidil’s meaningful commercial exclusivity expired decades ago. The compound was developed in the 1980s, and any original composition-of-matter and early clinical-use patent rights would have reached the end of their ordinary terms long before the present period.

The precise patent family and expiration dates are difficult to map into a current commercial estate because:

1. Pinacidil was not commercialized as an active U.S. reference product.
2. Historical patents may have been assigned to predecessor entities or subsidiaries.
3. Early patent terms depended on filing dates and the applicable national patent law.
4. Current patent databases do not indicate a meaningful blocking estate around the base compound.

A practical freedom-to-operate assessment would therefore focus less on the original pinacidil molecule and more on any new patent claims covering:

• A novel formulation
• A new delivery system
• A new therapeutic indication
• A combination therapy
• A specific salt, polymorph, or crystalline form
• A manufacturing process
• A biomarker-selected patient population

No widely recognized, commercially relevant active patent estate currently protects pinacidil as a conventional antihypertensive.

How many patents cover pinacidil?

The number of historical patent documents mentioning pinacidil is likely materially higher than the number of enforceable patents that could restrict commercial development today. Patent references may cover the molecule, potassium-channel modulators as a class, antihypertensive compositions, topical formulations, or experimental uses.

The commercially relevant count is effectively zero for an original-molecule blocking estate based on publicly documented market status. A historical patent search may identify numerous expired documents, but those should not be treated as current exclusivity.

Patent category	Current commercial significance
Original compound patents	Likely expired
Broad potassium-channel opener patents	Generally expired or difficult to enforce against old chemistry
Antihypertensive method patents	Historical; no current branded product identified
Hair-growth use patents	Potentially relevant only to newly claimed formulations or indications
Formulation patents	No major active estate publicly associated with a marketed pinacidil product
Manufacturing patents	Could matter for process-specific claims, but no recognized market barrier is established
U.S. Orange Book patents	None identified

What formulations are protected by pinacidil patents?

No commercially important pinacidil formulation franchise is currently established. The compound has appeared in research formulations, experimental preparations, and topical or laboratory settings, but these uses do not create the regulatory or economic position of an approved pharmaceutical formulation.

A future sponsor could seek protection for a formulation that improves:

• Oral absorption
• Dose control
• Reduction of reflex tachycardia
• Reduction of systemic exposure
• Topical follicular delivery
• Targeted vascular delivery
• Combination use with another cardiovascular agent

Formulation patents would need to demonstrate a meaningful technical difference from historical pinacidil preparations. A simple conventional tablet or solution would face weak patentability and limited commercial differentiation.

What happened to pinacidil’s commercial development?

Pinacidil entered development during a period when potassium-channel activation was viewed as a promising approach to vasodilation. The mechanism produced antihypertensive activity, but commercial development encountered several disadvantages.

First, the drug’s adverse-effect profile limited use. Vasodilation could trigger reflex tachycardia and fluid retention, requiring clinical management. Hypertrichosis also reduced acceptability, especially compared with antihypertensive drugs with more predictable tolerability.

Second, the market moved toward therapies with stronger physician familiarity, broader trial evidence, and simpler dosing. ACE inhibitors, angiotensin-receptor blockers, calcium-channel blockers, and thiazide diuretics became entrenched across treatment guidelines and formularies.

Third, potassium-channel opening created mechanistic and safety concerns. Systemic potassium-channel modulation can affect cardiovascular electrophysiology and vascular responses. The clinical benefit was not sufficient to offset the development and monitoring burden.

The result was a short commercial life followed by practical obsolescence as a prescription drug.

What is the financial trajectory of pinacidil?

Pinacidil has no separately disclosed current revenue, product-level operating income, or active commercial forecast from a major pharmaceutical company. Its financial trajectory is best described as:

1. Research-stage discovery and development
2. Limited historical antihypertensive commercialization
3. Loss of commercial relevance after safety and competitive disadvantages
4. Residual research and laboratory demand

Period	Financial position
1980s development period	Investment centered on discovery, clinical testing, and regulatory development
Historical launch period	Limited prescription-product revenue in selected markets
Post-commercial period	Declining sales and withdrawal or discontinuation from routine clinical use
Current period	No established branded pharmaceutical revenue; research-use demand only

No reliable public revenue series supports a precise compound-level valuation. Pinacidil should not be modeled as a growth pharmaceutical asset. Its current value is more closely related to licensing of experimental ion-channel programs, research reagents, or repurposing concepts than to direct sales of pinacidil tablets.

Could pinacidil generate future pharmaceutical revenue?

A future revenue opportunity would require a new development thesis. The most plausible routes are:

• A topical product designed to exploit potassium-channel activity in hair follicles
• A targeted vascular product that reduces systemic adverse effects
• A combination product for resistant hypertension
• A research or clinical tool for ATP-sensitive potassium-channel disorders
• A formulation with materially improved tolerability

Each route would require new clinical evidence. Historical antihypertensive data alone would not support a credible relaunch, particularly because multiple low-cost generic therapies already control the primary indication.

How does pinacidil compare with competing drugs?

Pinacidil is commercially weaker than established potassium-channel-related drugs and much weaker than mainstream antihypertensives.

Drug or class	Primary use	Regulatory and commercial position	Competitive effect on pinacidil
Minoxidil	Resistant hypertension; topical hair growth	Approved and commercially established	Strong substitute in relevant use cases
Diazoxide	Hyperinsulinemic hypoglycemia; historical antihypertensive use	Approved in defined indications	Competes mechanistically in specialized settings
Nicorandil	Angina in selected markets	Commercially available in some jurisdictions	Demonstrates continued but narrow use of vasodilator mechanisms
Amlodipine	Hypertension and angina	Broad global generic use	Stronger standard-of-care competitor
Losartan and other ARBs	Hypertension and cardiovascular risk reduction	Broad global generic use	Stronger efficacy, familiarity, and reimbursement position
ACE inhibitors	Hypertension and cardiovascular disease	Broad global generic use	Lower-cost, guideline-supported alternatives

Minoxidil is the closest commercial comparator when pinacidil is considered for hair-growth research. The compounds differ in approved status, clinical evidence, formulation history, and market access. Pinacidil has no equivalent commercial position in the consumer or prescription hair-growth market.

What generic entry risks exist for pinacidil?

A conventional generic-entry event is unlikely because there is no active U.S. reference product. The main risks are instead development and market-access risks.

Regulatory risk

A sponsor seeking to commercialize pinacidil in the United States would likely need a full clinical development program. That requirement materially increases cost and timeline compared with an ordinary ANDA strategy.

Clinical risk

The historical adverse-effect profile creates uncertainty over whether a modern trial could establish a favorable benefit-risk balance. A new indication would need to offer a clinically meaningful advantage over existing therapies.

Commercial risk

The active antihypertensive market is highly genericized. A newly developed pinacidil product would need a differentiated indication, delivery system, or safety profile to command pricing.

Patent risk

Original compound patents are unlikely to block entry. Risk would arise from later patents covering a new formulation, delivery technology, combination, or indication. Such claims would need to be reviewed by jurisdiction and claim scope.

Manufacturing and supply risk

Pinacidil is a small-molecule compound with no apparent manufacturing complexity comparable to biologics, sterile injectables, or highly potent oncology agents. Manufacturing is therefore unlikely to be the principal barrier. The larger barriers are clinical validation, regulatory approval, commercial positioning, and reimbursement.

Which companies are challenging or licensing pinacidil?

No major active Paragraph IV challenger, biosimilar sponsor, or publicly documented licensing campaign is associated with pinacidil. The compound is not positioned as a current branded asset with an identifiable originator-versus-generic dispute.

Historical development was associated with Upjohn, but the relevant commercial rights would have passed through corporate successor structures and are not clearly represented by an active pinacidil franchise. Pfizer acquired Warner-Lambert, which included the Upjohn business, and later separated or recombined assets through corporate transactions. No current public disclosure identifies pinacidil as a material Pfizer revenue product or strategic licensing asset.

What is the patent strength of pinacidil?

Pinacidil’s patent strength is weak for the original molecule and potentially moderate only for a genuinely novel follow-on product.

Asset type	Patent strength assessment
Original pinacidil molecule	Weak; historical rights expired
Basic antihypertensive use	Weak; old clinical concept
Standard oral formulation	Weak unless technically differentiated
Topical delivery	Potentially stronger if supported by new data
Combination therapy	Case-specific; dependent on inventive step and clinical benefit
Novel indication	Potentially protectable but requires credible clinical evidence
Manufacturing process	Potentially protectable if non-obvious and commercially useful
Biomarker-selected use	Potentially strong if the patient-selection method is novel and validated

The strongest future intellectual-property strategy would likely combine a narrowly defined clinical indication with a differentiated delivery system and supporting pharmacokinetic or pharmacodynamic data. Broad claims to potassium-channel activation would face substantial prior-art pressure.

What is the investment outlook for pinacidil?

Pinacidil is not an investable commercial pharmaceutical franchise on the basis of historical antihypertensive use alone. A financing case would require a new asset around the molecule rather than the molecule itself.

The investment profile is:

• Current product revenue: negligible or absent
• FDA approval value: absent
• Generic competition: high if approval were obtained
• Original patent protection: effectively exhausted
• Clinical redevelopment cost: potentially substantial
• Manufacturing difficulty: relatively low
• Differentiation requirement: very high
• Strategic value: limited to repurposing or research platforms

A sponsor could justify investment only if preclinical or early clinical data showed a clear advantage in a focused indication. Without that evidence, pinacidil is more likely to remain a historical pharmacology tool than a revived pharmaceutical product.

Key Takeaways

• Pinacidil is an ATP-sensitive potassium-channel opener developed primarily for hypertension.
• It is not FDA approved and has no current U.S. reference product or Orange Book listing.
• No standard Paragraph IV generic challenge or biosimilar pathway applies.
• Original compound and early-use patent protection are effectively expired.
• No current branded revenue stream or reliable public product-level financial forecast exists.
• Historical commercial performance was constrained by tolerability, safety, and competition from established antihypertensive classes.
• Research use remains possible, but research demand does not support a conventional pharmaceutical valuation.
• A viable redevelopment strategy would require a new indication, improved delivery system, or materially better safety profile.
• The most relevant commercial comparison for hair-growth research is minoxidil, while the principal cardiovascular competitors are low-cost generic antihypertensives.
• Pinacidil’s original-molecule patent estate is weak; follow-on formulation and method-of-use patents could create value only if supported by new clinical evidence.

FAQs About Pinacidil Market and Patent Status

Is pinacidil still sold as a prescription medicine?

Pinacidil is not an active FDA-approved U.S. prescription product. Historical non-U.S. commercialization did not develop into a durable global pharmaceutical franchise.

Does pinacidil have an Orange Book patent?

No current Orange Book listing for an FDA-approved pinacidil reference product has been identified. As a result, there is no established Orange Book patent-expiration timetable for pinacidil.

Can a company file an ANDA for pinacidil?

An ANDA generally requires a reference listed drug. Because pinacidil has no established U.S. reference product, a sponsor would likely need a full regulatory development strategy rather than a conventional generic filing.

Is pinacidil the same as minoxidil?

No. Both compounds can open potassium channels and have been studied in relation to vascular or hair-follicle effects, but they are different chemical entities. Minoxidil has established FDA-approved uses; pinacidil does not have an equivalent current U.S. approval.

Does pinacidil have commercial potential in hair loss?

Only as a redevelopment hypothesis. Historical pharmacology supports research interest, but commercial development would require new clinical trials, a differentiated delivery system, and evidence that pinacidil offers an advantage over minoxidil or other hair-loss treatments.

References

1. National Center for Biotechnology Information. (n.d.). PubChem compound summary for CID 4823, Pinacidil. PubChem.
2. U.S. Food and Drug Administration. (n.d.). Drugs@FDA: FDA-approved drugs.
3. U.S. National Library of Medicine. (n.d.). Pinacidil. MedlinePlus and related drug information resources.
4. U.S. Food and Drug Administration. (n.d.). Approved drug products with therapeutic equivalence evaluations. Orange Book.
5. Edwards, G., & Weston, A. H. (1990). Structure-activity relationships of K+ channel openers. Trends in Pharmacological Sciences, 11(10), 417-422.
6. U.S. Food and Drug Administration. (n.d.). Purple Book: Database of licensed biological products.